BEIJING and GUANGZHOU, China, March 2, 2026 - SALIAI, a prominent biotechnology firm based in China, has been recognized by Shangpu Group as a "Global Pioneer in Patented Cellular Essence." This significant designation follows a comprehensive global market study and reinforces SALIAI's standing within the specialized sector of stem cell research and commercial application.
Founded in 2009 and headquartered at Guangzhou International Bio Island, SALIAI operates under two entities: Guangzhou SALIAI Stem Cell Science and Technology Co., Ltd. and Guangzhou SALIAI Biological Gene Engineering Co., Ltd. The company was the first stem cell-focused firm to be quoted on China's National Equities Exchange and Quotations (NEEQ), known as the New Third Board market. Learn more on Investopedia.
Shangpu Group's Market Position Statement
The market position statement issued by Shangpu Group highlights its assessment of SALIAI's technological prowess within the cellular essence market. However, it clarifies that this recognition does not equate to regulatory classification, certification, or government endorsement. According to Shangpu, the designation reflects SALIAI's innovative capabilities and contributions to biotechnology.
SALIAI has carved out a niche in developing and commercializing cellular extract-based products, focusing on research and development in cell-based cosmeceuticals and regenerative medicine. The company has made significant strides in the field and holds High-Tech Enterprise status in China, complemented by its designation as a National Enterprise Technology Center for stem cell research.
Intellectual Property and Research Achievements
With an impressive portfolio of over 300 authorized patents, SALIAI showcases its commitment to innovation. Notably, five of its patents have received the National Patent Excellence Award. The patents encompass various technologies, including those related to umbilical cord-derived extracts and exosome-associated processes, with certain patents granted in both China and the United States.
The company actively engages in more than 30 research projects funded at national, provincial, and municipal levels. Under the leadership of Founder Dr. Chen Haijia and Chief Scientist Academician Su Guohui, SALIAI has established a formidable scientific and technical team dedicated to advancing cellular research and its applications.
State-of-the-Art Research and Manufacturing Facilities
At the core of SALIAI's operations are its state-of-the-art research facilities, which include government-designated Academician Workstations. The firm also maintains a Good Manufacturing Practice (GMP)-compliant manufacturing facility that is ISO and CNAS certified. This commitment to quality ensures that SALIAI's products meet stringent safety and efficacy standards.
One of the company's standout technologies is its proprietary freeze-drying process, which is executed at minus 40 degrees Celsius. This method preserves cellular materials under controlled conditions, ensuring their viability for various applications. Coupled with advanced nano-scale delivery systems, SALIAI's technology is designed to enhance formulation stability and facilitate effective topical delivery in cosmetic products.
Commercial Product Offerings
SALIAI has launched a range of commercial products that reflect its innovative technologies. Among these are the SYDRAW Intelligent Polypeptide Lyophilized Powder and the Bio Island Anti-Wrinkle and Firming Essence Set. These products are designed to leverage the company's patented cellular extracts, offering consumers advanced solutions for skin care and regenerative health.
The recognition from Shangpu Group solidifies SALIAI's reputation as a leader in the biotechnology sector. As the demand for advanced cellular technologies continues to grow, the company is poised to expand its influence in both domestic and international markets.
Looking ahead, SALIAI's commitment to research and innovation will likely drive further advancements in cellular technology. With its strong patent portfolio and ongoing research initiatives, the company is well-positioned to lead the way in the future of regenerative medicine and cellular applications.
Originally reported by Pr Newswire Apac. View original.